Research
Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis
Nandini Dendukuri, Karim Khetani, Michelle McIsaac and James Brophy
CMAJ May 08, 2007 176 (10) 1429-1434; DOI: https://doi.org/10.1503/cmaj.061011
Nandini Dendukuri
Karim Khetani
Michelle McIsaac
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis
Nandini Dendukuri, Karim Khetani, Michelle McIsaac, James Brophy
CMAJ May 2007, 176 (10) 1429-1434; DOI: 10.1503/cmaj.061011
Jump to section
Related Articles
Cited By...
- Breast Cancer Subtype Classification Using 4-Plex Droplet Digital PCR
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
- Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study
- Multiple Protein Analysis of Formalin-fixed and Paraffin-embedded Tissue Samples with Reverse phase Protein Arrays
- HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy
- HER2 Codon 655 G-Allele Is Associated With Reductions in Plasma High-Density Lipoprotein Levels in Breast Cancer Patients Treated With Tamoxifen
- Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?
- Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies
- Reply to V. Arena et al
- Trastuzumab for Patients With Axillary-Node-Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
- HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- Up-regulation of Acetyl-CoA Carboxylase {alpha} and Fatty Acid Synthase by Human Epidermal Growth Factor Receptor 2 at the Translational Level in Breast Cancer Cells
- HER2 testing: The patent "genee" is out of the bottle